Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
Mattei MF, Redonnet M, Gandjbakhch I, Bandini AM, Billes A, Epailly E, Guillemain R, Lelong B, Pol A, Treilhaud M, Vermes E, Dorent R, Lemay D, Blanc AS, Boissonnat P.
Mattei MF, et al. Among authors: lelong b.
J Heart Lung Transplant. 2007 Jul;26(7):693-9. doi: 10.1016/j.healun.2007.05.002.
J Heart Lung Transplant. 2007.
PMID: 17613399
Clinical Trial.